GSK 6-K
GSK plc (GSK)
6-K
2026-02-17
For: 2026-02-17
View Original
Added on
July 04, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADS') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in February 2023 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions, and the subsequent sale of Ordinary Shares and ADS to meet tax liabilities. The three-year performance period for these awards commenced on 1 January 2023 and ended on 31 December 2025. The awards vested on 13 February 2026.
The performance measure outcomes and vesting levels for these awards are set out in the following table.
| Outcome and Vesting Level | |||
|---|---|---|---|
| Portion of the Award | Measure and Outcome | % of maximum | % of award |
| 30% | Total Shareholder Return -<br>For the three-year period the Company's Total Shareholder Return<br>ranked 5th, against a comparator group of 10 global pharmaceutical<br>companies including GSK. | 40% | 12% |
| 20% | Total Sales - For the<br>three-year period, the Company achieved sales across our marketed<br>products for the measure of £99.03bn, which is above the level<br>of £94.58bn required for 100% vesting. The threshold<br>vesting level was £89.18bn. | 100% | 20% |
| 20% | Total Profit - For the<br>three-year period, the Company achieved £30.22bn, which<br>is above the level of £29.43bn required for 100%<br>vesting. The threshold vesting level was<br>£27.75bn. | 100% | 20% |
| 20% | Pipeline Progress - Measure is equally weighted<br>between:<br><br>-<br>Pivotal trial starts<br><br>-<br>Major regulatory approvals | 100%<br><br><br>100% | 10%<br><br><br>10% |
| 10% | Responsible Business: Environment - For the three-year period, all criteria for<br>achieving our Trust priority and goal of having a Nature Net<br>Positive and Climate Net Zero impact by 2030 have been met or<br>exceeded in advance of the target date required to result in<br>maximum vesting for this measure. | 100% | 10% |
| Total vesting for 2023 award<br><br><br>Lapsed | 82%<br><br><br>18% | 82% |
The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued during the vesting period, on 13 February 2026. The balance of the award made to each PDMR and PCA has lapsed.
The closing prices of Ordinary Shares and of ADS of GSK plc on the vesting date were £21.65 and $58.93.
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 245,716 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 15,579 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,908 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 4,240 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 102,653 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 54,951 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,908 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 4,255 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 159,845 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 75,128 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 42,631 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The sale of ADS to meet tax liabilities on the vesting of awards<br>granted in 2023 under the Company's 2017 Performance Share<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $58.8509 | 15,630.222 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,908 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 2,880 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 59,379 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The sale of ADS to meet tax liabilities on the vesting of awards<br>granted in 2023 under the Company's 2017 Performance Share<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $58.8509 | 30,806 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 171,300 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 80,511 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 173,295 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 81,449 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Phil Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 79,007 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Phil Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 37,134 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 162,949 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 76,587 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 219,851 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 103,330 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP & Company Secretary | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,908 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP & Company Secretary | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 5,127 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of awards granted in 2023 under the Company's 2017<br>Performance Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,908 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial<br>notification/<br><br>amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary Shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's 2017 Performance<br>Share Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.6002 | 5,259 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume Price | |||||
| e) | Date<br>of the transaction | 2026-02-13 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: February<br>17, 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |